Newsroom

Industry News

10 Nov

Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference

PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets cancers caused by human papillomavirus (HPV) types 16 and...

Read more

9 Nov

BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, November 9, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before...

Read more

9 Nov

Nephros Reports Third Quarter 2017 Financial Results

RIVER EDGE, NJ–(Marketwired – Nov 9, 2017) – Nephros, Inc. ( OTCQB : NEPH ) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage...

Read more

9 Nov

Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare Conference Presentation and 1×1 meetings Dr. Niranjan Y. Sardesai, COO 11:45 AM ET, November 15, 2017 New York, NY 29th Annual...

Read more

9 Nov

OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec’s Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer Agents OncoSec Presents Emerging Preclinical Data Demonstrating its Novel Platform at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting SAN DIEGO, Nov. 9, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing...

Read more

9 Nov

IsoRay, Inc. Announces the Launch of a Phase II, Multicenter Clinical Trial with Cesium-131 Adjuvant Radiation for Retroperitoneal Sarcoma Delivery System (CARDS Trial) by University of Louisville, Division of Surgical Oncology

RICHLAND, Wash., Nov. 09, 2017 (GLOBE NEWSWIRE) — IsoRay, Inc. (ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of a Phase II, Multicenter Clinical Trial with...

Read more

9 Nov

Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee

COSTA MESA, CA–(Marketwired – Nov 9, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) (the “Company”) today announced that it has submitted a demand commencing arbitration against Schneider Finance, LLC and SB Securities, Ltd., both affiliates of Schneider Brothers Ltd., as well as other individuals. SB Securities, Ltd. also uses the name “Schneider...

Read more

9 Nov

Aemetis, Inc. Reports Third Quarter 2017 Financial Results

CUPERTINO, CA / ACCESSWIRE / November 9, 2017 / Aemetis, Inc. (AMTX), an advanced renewable fuels and biochemicals company, today announced its financial results for the three and nine months ended September 30, 2017. During the third quarter of 2017, year over year revenues for North America increased to $36.0...

Read more

9 Nov

Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

Company Opens European Subsidiary in Spain to Support Global Clinical Development Nine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW YORK and CLEVELAND, Nov. 09, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing...

Read more

9 Nov

Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2017. The company is issuing this press release in lieu of conducting a conference call. “We are excited by our continued clinical research...

Read more

Page 3 of 26812345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address